Contrary to the vaccine manufacturer’s pronouncement, a new study found that a third dose of Sinovac’s Covid-19 vaccine does not provide sufficient protection against the Omicron variant.
According to Nikkei Asia, the University of Hong Kong (HKU) and the Chinese University of Hong Kong conducted the study and found that a third injection of what is one of the most widely used Covid-19 vaccines in the world does not produce sufficient levels of virus. . -neutralizing antibodies.
However, the third dose of a vaccine produced by Pfizer and BioNTech significantly improved protection for those who had previously taken two doses of Sinovac, also known as CoronaVac, the study indicated.
A booster from Pfizer “will achieve optimal protection against (the) Omicron variant,” said Malik Peiris, the HKU professor who led the research.
Last week, Sinovac said his own study had found a third dose to be “effective in enhancing serum neutralization against the omicron strain.”
He said 94 percent of those who had received three doses of Sinovac generated enough neutralizing antibodies. The company did not elaborate on what kind of antibody levels three injections produced.
Sinovac did not respond to requests for comment.
CoronaVac is one of two Chinese vaccines approved by the World Health Organization (WHO) for emergency use.